We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
13
3 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
2
15.4%
Completed
6
46.1%
Enrolling By Invitation
1
7.7%
Recruiting
4
30.8%
No approval data available
- DelveInsight reports over 50 pharmaceutical companies are actively developing 55+ cannabinoid therapies across various clinical stages, representing significant momentum in the therapeutic cannabis space. - Recent clinical milestones include positive Phase II results for IGC-AD1 in Alzheimer's agitation, FDA orphan drug designation for BRC-002 in complex regional pain syndrome, and successful Phase I completion for OCT461201. - Leading pipeline candidates target diverse conditions including neurodegenerative diseases, chronic pain, epilepsy, and inflammatory disorders, with multiple drugs advancing through Phase II and Phase III trials. - The expanding pipeline reflects growing clinical validation for cannabinoids in treating conditions like Alzheimer's disease, chronic pain, and rare epilepsy syndromes, supported by increasing medical cannabis legalization.
